QIAGEN appoints Jonathan M. Pratt as CEO
Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall
Advertisement
QIAGEN N.V. announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare.
Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corporation in August 2026. He previously served as Senior Vice President of the Waters Division at Waters Corporation and as President of Beckman Coulter Life Sciences, a Danaher operating company, and held senior leadership positions at Pall Corporation.
Throughout his career, he has led global businesses spanning analytical instruments, laboratory technologies, software, consumables, services and bioprocessing applications. His experience includes commercial execution, portfolio management, operations and organizational development in markets closely aligned with QIAGEN’s portfolio and customer workflows.
The appointment follows a comprehensive search process. Jon Pratt was selected for his global industry knowledge, international leadership experience and proven track record of improving performance across global businesses. He will also be proposed for shareholder approval as a Managing Director at an Extraordinary General Meeting planned for the fourth quarter of 2026.
“The Supervisory Board unanimously concluded that Jon Pratt is the right leader for QIAGEN’s next phase,” said Stephen H. Rusckowski, Chairman of the Supervisory Board of QIAGEN. “Jon combines deep knowledge of our markets with a strong international record of strengthening commercial execution and operational performance. His experience across life sciences and laboratory technologies is directly relevant to QIAGEN’s portfolio and customers. Building on our strong foundation, we are confident he will advance our commitment to solid profitable growth. On behalf of the Supervisory Board, I also want to thank Thierry Bernard for his leadership, his many contributions to QIAGEN and his support in ensuring continuity during this transition.”
“QIAGEN is an iconic and trusted brand in life sciences and molecular diagnostics, built on scientific rigor, quality and technologies that support critical laboratory workflows worldwide,” Jon Pratt said. “What attracted me to QIAGEN is the combination of talented teams, a differentiated portfolio and close customer relationships. My first priority will be to listen to QIAGEN teams and customers, learn more about the business and understand where we can sharpen our choices, strengthen execution and create greater impact. I look forward to working with the team to advance our vision of making improvements in life possible.”
Thierry Bernard will step down as CEO and Managing Director and will support an orderly transition through the end of the year.
QIAGEN has reaffirmed its outlook for the third quarter and full-year 2026. QIAGEN remains focused on delivering solid profitable growth by advancing its growth pillars, improving operating efficiency and allocating capital to the highest-return opportunities.
As previously communicated, the Supervisory Board continues to evaluate opportunities, with independent financial and legal advisors, as part of its strategic review to create value for shareholders and other stakeholders relative to QIAGEN’s standalone business plan and long-term strategic objectives.
About Jonathan M. Pratt
Jon Pratt is an experienced global executive with more than 25 years of leadership experience across life sciences, laboratory technologies and healthcare. Before joining QIAGEN, he served as President and Chief Executive Officer of Filtration Group, a global filtration and separation science company, where he led the business through continued growth and the completion of its sale to Parker-Hannifin Corporation in August 2026. He previously served as Senior Vice President of the Waters Division at Waters Corporation and as President of Beckman Coulter Life Sciences, a Danaher operating company, and held senior leadership positions at Pall Corporation. He holds a Bachelor of Science in chemistry from the University of Reading in the United Kingdom and an MBA from New York University Stern School of Business.
Other news from the department people
